3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Melanoma
11
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Carcinoma, Merkel Cell
2
Squamous Cell Carcinoma of Head and Neck
1
Peritoneal Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Cutaneous
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Carcinoma, Ductal, Breast
1
Carcinoma, Ductal
1
Carcinoma, Basal Cell
1
Advanced Non CNS Tumors
1
Adenocarcinoma
1
Interventions
HhAntag691
18
Imiquimod
10
sonidegib
8
Photochemotherapy
7
1-phenyl-3,3-dimethyltriazene
6
methyl 5-aminolevulinate
4
Surgical Procedures, Operative
4
Biopsy
4
Aminolevulinic Acid
4
cemiplimab
3
Mohs Surgery
3
Microscopy, Confocal
3
Itraconazole
3
IPI-926
3
3-ingenyl angelate
3
tazarotene
2
Microarray Analysis
2
Laser Therapy
2
Gene Expression Profiling
2
Eflornithine
2
Drug Evaluation
2
Acitretin
2
tozuleristide
1
teriflunomide
1
talimogene laherparepvec
1
silmitasertib
1
remetinostat
1
pembrolizumab
1
gusacitinib
1
green tea extract polyphenone E
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Basal Cell
×
talimogene laherparepvec
×
Clear all
NCT03458117
2022-03-18
20139157 T-VEC
University of Zurich
Phase 1
Completed
26 enrolled